Pfizer begins Phase II with IPIC's pagoclone

Interneuron (IPIC) said that partner PFE began a double-blind, placebo-controlled Phase II trial of pagoclone, a cyclopyrrolone that affects GABA neurotransmission, to treat generalized anxiety disord...